Barrett's esophagus consists of a precancerous condition in which the progression from dysplasia to adenocarcinoma is now well documented. The management of patients affected by Barrett's esophagus is still debatable, in particular for the risk of surgical treatment in the presence of small precancerous lesions or early adenocarcinoma. Furthermore, quality of life after surgical resection is often poor. Endoscopy is the main diagnostic and follow-up procedure in Barrett's esophagus: it allows the detection and treatment of severe dysplasia and invasive esophageal adenocarcinoma. Endoscopic treatment also produces reduction or disappearance of intestinal metaplasia. In these cases, the aim of the treatment is to prevent dysplastic changes. Moreover, the ideal endoscopic treatment should be safe, easy to perform and cost effective. Thermal (electrocoagulation, laser, argon-plasma coagulation), photochemical (photodynamic therapy) or ablative (endoscopic mucosal resection) procedures have been proposed alone or in combination, with the aim to completely eradicate dysplastic lesions or early adenocarcinoma as an alternative to surgical treatment. Endoscopic removal of the lesions is followed by restoration of normal epithelium. Some questions about patient selection, prevention of recurrence and best endoscopic treatment still remain unanswered.
Limited Resection for Early Adenocarcinoma in Barrett’s Esophagus